Changes on Bone Mineral Density after Adjuvant Treatment in Women with Non-metastatic Breast Cancer

2005 ◽  
Vol 93 (1) ◽  
pp. 75-83 ◽  
Author(s):  
Luz-Milva Rodríguez-Rodríguez ◽  
Eva-María Rodríguez-Rodríguez ◽  
Juana-María Oramas-Rodríguez ◽  
Francisco Santolaria-Fernandez ◽  
Marta Llanos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Metastatic Breast Cancer ◽  
Bone Mineral ◽  
Adjuvant Treatment ◽  
Metastatic Breast ◽  
Mineral Density

Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy.

1998 ◽  
Vol 16 (1) ◽  
pp. 348-353 ◽  
Author(s):  
A U Buzdar ◽  
G N Hortobagyi
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Endometrial Cancer ◽  
Metastatic Breast Cancer ◽  
Bone Mineral ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Cardiac Events ◽  
Mineral Density

PURPOSE Tamoxifen is currently the standard hormonal treatment of breast cancer, both for metastatic disease and in the adjuvant setting. A new antiestrogen, toremifene, was approved recently for use in managing metastatic breast cancer in postmenopausal women. METHODS Toremifene is structurally similar to tamoxifen, differing only by a single chlorine atom, and has a similar pharmacologic profile. The major difference between the two compounds is in the preclinical activity; chronic, high-dose tamoxifen is hepatocarcinogenic in the rat, whereas toremifene is not. Neither agent is hepatocarcinogenic in mice, hamsters, or humans; therefore, clinical relevance of the rat data may not be significant. RESULTS In a worldwide phase III trial, the two agents demonstrated comparable efficacy and safety against metastatic breast cancer. Both agents have shown a significant hypocholesterolemic effect after long-term administration. CONCLUSION Due to the paucity of long-term clinical data on toremifene, important unresolved questions remain, which include its effects on bone mineral density, the frequency of cardiac events, and the risk for endometrial cancer. Tamoxifen has been associated with maintenance of bone mineral density, a reduction in cardiac events, and a slightly increased risk of endometrial cancer. Toremifene is not likely to be used as second-line therapy after tamoxifen failure due to cross-resistance, and its ultimate place in therapy of advanced breast cancer remains to be determined.

Effects of One-Year Adjuvant Treatment with Tamoxifen on Bone Mineral Density in Postmenopausal Breast Cancer Women

1996 ◽  
Vol 82 (1) ◽  
pp. 65-67 ◽  
Author(s):  
Sandro Barni ◽  
Paolo Lissoni ◽  
Gabriele Tancini ◽  
Antonio Ardizzoia ◽  
Marina Cazzaniga
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Bone Mineral Content ◽  
Bone Mineral ◽  
Adjuvant Treatment ◽  
Mineral Content ◽  
Postmenopausal Breast Cancer ◽  
Mineral Density ◽  
One Year

In this study, the authors have analyzed the possible effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women. Bone mineral content was studied by photon absorptiometry (I-125), whereas bone balance was analyzed indirectly by serum PTH, osteocalcin, calcitonin, calcium and alkaline phosphatase levels. Bone mineral content and serum bone-related substances were measured before starting treatment and after one year. Results were analyzed using Student's t test for paired data. No difference was found between the two measurements for bone mineral content, PTH, calcitonin, calcium and alkaline phosphatase levels. Measurements at entry and after one year of treatment showed a statistically significant difference ( P < 0.001) only for osteocalcin. In accordance with other authors, we can conclude that treatment with tamoxifen does not cause an increase in menopausal bone resorption. The finding that osteocalcin levels decreased after one year of therapy with tamoxifen is interesting, but further studies are necessary to clarify the role of such levels in predicting a turnover of bone balance towards osteoblastic activity.

Sign in / Sign up

Export Citation Format

Share Document